Shares of Humacyte Inc (NASDAQ: HUMA) nearly doubled on Friday after receiving full approval for its flagship SYMVESS product from the US Food and Drug Administration (FDA). Regulatory approval for the company’s bioengineered human tissue marks a major step forward in regenerative medicine and trauma care. Humacyte stock sure has…
The latest economic data reveals a welcome moderation in inflation, as the personal consumption expenditures (PCE) price index rose…
This week, the LATAM cryptocurrency landscape demonstrated its dynamic nature once more. El Salvador has decided to continue with…
Southeast Asia, a region of over 675 million people, is emerging as a focal point for global investment in…
Thwarted expectations of up to 4 rate cuts in 2025 have sent US stocks tumbling down in recent days.…
Investors are bailing on Micron Technology Inc (NASDAQ: MU) this morning after the chipmaker issued guidance for its current…
The United Nations reported on Wednesday that the economies of Latin America and the Caribbean are expected to rise…
Bank of America Securities recently warned that Advanced Micro Devices Inc (NASDAQ: AMD) could find it incrementally difficult to…
The US stock market experienced a rather aggressive sell-off on Wednesday after the Federal Open Market Committee signalled less-than-expected…